New antiviral agents for the therapy of chronic hepatitis B virus infection

被引:26
作者
Zoulim, F [1 ]
Trepo, C [1 ]
机构
[1] Hop Hotel Dieu, Liver Unit, Lyon, France
关键词
chronic hepatitis B; hepadnaviridae; hepatitis B virus; antiviral therapy; nucleoside analogs; viral resistance;
D O I
10.1159/000024972
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The development of new antiviral strategies for the treatment of chronic hepatitis B remains a major goal since hepatitis virus (HBV) is resistant to interferon treatment as well as to new nucleoside analogs. HBV is a small DNA virus that replicates its genome via a reverse transcription step. The viral polymerase has been the main viral target that was studied to design new antiviral treatments. Active research has led to the discovery of new nucleoside analogs that are potent inhibitors of the viral reverse transcriptase. Among them, lamivudine has also proven antiviral efficacy in clinical trials with a sustained inhibition of viral replication. However, due to the kinetics of viral clearance, long-term antiviral therapy is necessary to eradicate viral infection. These prolonged regimens are associated with the emergence of drug-resistant strains that harbor mutations in the viral polymerase gene within-the conserved B and C domains. New approaches using combinations of nucleoside analogs or other strategies, such as immune intervention (DNA vaccine, stimulation of the TH1 response) or gene therapy (antisense oligonucleotides, dominant negative mutants), should therefore be evaluated in animal models to optimize the current antiviral protocols.
引用
收藏
页码:125 / 144
页数:20
相关论文
共 162 条
[121]   PRODUCTION OF HEPATITIS-B VIRUS-PARTICLES IN HEP-G2 CELLS TRANSFECTED WITH CLONED HEPATITIS-B VIRUS-DNA [J].
SELLS, MA ;
CHEN, ML ;
ACS, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (04) :1005-1009
[122]   REPLICATIVE INTERMEDIATES OF HEPATITIS-B VIRUS IN HEPG2 CELLS THAT PRODUCE INFECTIOUS VIRIONS [J].
SELLS, MA ;
ZELENT, AZ ;
SHVARTSMAN, M ;
ACS, G .
JOURNAL OF VIROLOGY, 1988, 62 (08) :2836-2844
[123]   MECHANISM OF INHIBITION OF DUCK HEPATITIS-B VIRUS POLYMERASE BY (-)-BETA-L-2',3'-DIDEOXY-3'-THIACYTIDINE [J].
SEVERINI, A ;
LIU, XY ;
WILSON, JS ;
TYRRELL, DLJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1430-1435
[124]  
Shaw T, 1996, HEPATOLOGY, V24, P996
[125]   IN-VITRO ANTIVIRAL ACTIVITY OF PENCICLOVIR, A NOVEL PURINE NUCLEOSIDE, AGAINST DUCK HEPATITIS-B VIRUS [J].
SHAW, T ;
AMOR, P ;
CIVITICO, G ;
BOYD, M ;
LOCARNINI, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :719-723
[126]  
Shields P. L., 1997, Hepatology, V26, p260A
[127]   Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene [J].
Stuyver, L ;
Wyseur, A ;
Rombout, A ;
Louwagie, J ;
Scarcez, T ;
Verhofstede, C ;
Rimland, D ;
Schinazi, RF ;
Rossau, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :284-291
[128]   3 RECENTLY DESCRIBED ANIMAL VIRUS MODELS FOR HUMAN HEPATITIS-B VIRUS [J].
SUMMERS, J .
HEPATOLOGY, 1981, 1 (02) :179-183
[129]   REPLICATION OF THE GENOME OF A HEPATITIS-B-LIKE VIRUS BY REVERSE TRANSCRIPTION OF AN RNA INTERMEDIATE [J].
SUMMERS, J ;
MASON, WS .
CELL, 1982, 29 (02) :403-415
[130]  
Tassopoulos N. C., 1998, Journal of Hepatology, V28, P43, DOI 10.1016/S0168-8278(98)80381-4